Skip navigation

Millie Das, M.D.

Clinical Focus

    Thoracic Oncology

Current Position

Staff Oncologist VA Palo Alto Health Care System, Palo Alto, CA
Clinical Assistant Professor Stanford University School of Medicine, Stanford, CA

Training & Professional Experience

2008-2011 Hematology/Oncology Fellowship Program, Stanford University School of Medicine, Stanford, CA
2007-2008 Hospitalist, Providence Everett Medical Center, Everett Clinic, Everett, WA
2004-2007 Internal Medicine Residency Program Stanford University School of Medicine, Stanford, CA
2000-2004 M.D., University of Massachusetts Medical School, Worcester, MA
1996-2000 B.S. in Biology, Minor in Literature, Massachusetts Institute of Technology, Cambridge, MA

Board Certification

    2011, American Board of Internal Medicine, Medical Oncology

    2007, American Board of Internal Medicine, Internal Medicine


2010 Henzl-Gabor Travel Fellow
2010 Kirby Wilcox Fellow
2010 Stanford Oncology Retreat Poster Session winner
2004 John S. Efstathiou Award for compassion, caring, and understanding in the care of patients and their families
2000 UMass Medical School Pathways Program
2000 MIT India Scholarship Recipient
1999 MIT Burchard Scholar of the Humanities


Das M*, Reiss J*, Hsieh HB, Krivacic RT, Lazarus N, Bennis R, Ly J, Schwartz E, Zhou L, Nieva J, Wakelee H, Bruce R. A quantitative assay of ERCC1 expression in circulating tumor cells (CTCs) in Non-small Cell Lung Cancer (NSCLC): a potential predictor of treatment response. Lung Cancer 2012 May 1. Epub ahead of print. Article.
Das M, Wakelee H. Targeting VEGF in Lung Cancer. Expert Opin Ther Targets 2012 Apr; 16(4): 395-406. Review.
Das M, Wakelee H. Angiogenesis Inhibitors. Journal of Thorac Oncol. 2011 Nov; 6(11 Suppl 4): S1801-2. Review.
Das M, Donington J, Murphy J, Kozak M, Eclov N, Whyte R, Hoang C, Zhou L, Le QT, Loo B, Wakelee H. Results from a Single Institution Phase II Trial of Concurrent Docetaxel/Carboplatin/Radiotherapy Followed by Surgical Resection and Consolidation Docetaxel/Carboplatin in Stage III Non-Small-Cell Lung Cancer (NSCLC). Clin Lung Cancer. 2011 Jul; 12(5): 280-5. Article.
Das M, Wakelee H. Stage IIIB and IV Disease NSCLC: Primary Therapy. Kernstine KH and Reckamp KL, (Eds). Lung Cancer: A Multidisciplinary Approach to Diagnosis and Management. New York: Demos Medical Publishing, LLC, 2011: 183-195. Chapter.
Das M, Wakelee H. Summary of the 10th annual `Targeted Therapies of the Treatment of Lung Cancer' meeting in Santa Monica: Vascular disrupting agents. Journal of Thorac Oncol. 2010 Nov; 5(12 Suppl 6): S482-3. Review.
Das M, Abdelmaksoud M, Loo B, Kothary N. Alternatives to Surgery for Early Stage Non-Small Cell Lung Cancer. Curr Treat Options Oncol. 2010 Jun; 11(1-2): 24-35. Review.
Roy MS, Le Q, Donington J, Wakelee H. Management of locally advanced non-small cell lung cancer from a surgical perspective. Curr Treat Options Oncol. 2007 Feb; 8(1): 1-14. Review.
Roy MS, Le Q, Donington J, Wakelee H. A multidisciplinary approach to management in a patient with bilateral superior sulcus non-small-cell lung carcinoma. Clin Lung Cancer. 2006 Sep; 8(2): 146-8. Case Report.
*Contributed equally.

Last modified 10-Feb-2012